Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

lawsuittortplaintiffregulation
tortplaintiffstatuteregulation

Related Cases

Pacific Mut. Life Ins. Co. v. Haslip, 499 U.S. 1, 111 S.Ct. 1032, 113 L.Ed.2d 1, 59 USLW 4157, 18 Media L. Rep. 1753
View Case »
Thomas v. Winchester, 2 Seld. 397, 6 N.Y. 397, 1852 WL 4748, 57 Am.Dec. 455
View Case »
Centocor, Inc. v. Hamilton, 372 S.W.3d 140, 55 Tex. Sup. Ct. J. 774
View Case »
Boos v. Barry, 485 U.S. 312, 108 S.Ct. 1157, 99 L.Ed.2d 333, 56 USLW 4254
View Case »
Kallstrom v. U.S., 43 P.3d 162
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

PLIVA, Inc. v. Mensing, 564 U.S. 604, 131 S.Ct. 2567, 180 L.Ed.2d 580, 79 USLW 4606, Prod.Liab.Rep. (CCH) P 18,642, 11 Cal. Daily Op. Serv. 7694, 2011 Daily Journal D.A.R. 9237, 22 Fla. L. Weekly Fed. S 1222

Facts

The plaintiffs, Gladys Mensing and Julie Demahy, were prescribed Reglan, a brand-name drug containing metoclopramide, but received the generic version from their pharmacists. After taking the drug for several years, both developed tardive dyskinesia, a severe neurological disorder. They filed separate lawsuits against the generic drug manufacturers, claiming that the manufacturers failed to provide adequate warning labels about the risks associated with long-term use of metoclopramide. The manufacturers argued that federal law pre-empted these state tort claims, as they were required to use the same labeling as the brand-name drug.

Gladys Mensing and Julie Demahy, the plaintiffs in these consolidated cases, were prescribed Reglan in 2001 and 2002, respectively. Both received generic metoclopramide from their pharmacists. After taking the drug as prescribed for several years, both women developed tardive dyskinesia.

Issue

Whether federal drug regulations applicable to generic drug manufacturers directly conflict with, and thus pre-empt, state tort claims based on inadequate warning labels.

The question presented is whether federal drug regulations applicable to generic drug manufacturers directly conflict with, and thus pre-empt, these state-law claims.

Rule

Federal law pre-empts state law when it is impossible for a private party to comply with both state and federal requirements.

Where state and federal law directly conflict, state law must give way.

Analysis

The Court analyzed the conflict between state tort duties, which required manufacturers to provide adequate warnings, and federal regulations, which mandated that generic drug labels must be the same as those of their brand-name counterparts. The Court found that it was impossible for the manufacturers to comply with both obligations simultaneously, as changing the label to meet state law would violate federal law.

The Court finds impossibility here. If the Manufacturers had independently changed their labels to satisfy their state-law duty to attach a safer label to their generic metoclopramide, they would have violated the federal requirement that generic drug labels be the same as the corresponding brand-name drug labels.

Conclusion

The Supreme Court reversed the judgments of the lower courts, holding that federal law pre-empted the state tort claims against the generic drug manufacturers.

The judgments are reversed, and the cases are remanded.

Who won?

The generic drug manufacturers prevailed in the case because the Supreme Court found that federal law pre-empted the state tort claims, making it impossible for the manufacturers to comply with both state and federal requirements.

The Manufacturers urged that federal law pre-empted the state tort claims. According to the Manufacturers, federal statutes and FDA regulations required them to use the same safety and efficacy labeling as their brand-name counterparts.

You must be